When cancer starts in the uterus, it is called uterine cancer. The uterus is the pear-shaped organ in a woman's pelvis (the area below your stomach and in between your hip bones). The uterus, also called the womb, is where the baby grows when a woman is pregnant. The most common type of uterine cancer is also called endometrial cancer because it forms in the lining of your uterus, called the endometrium.
When uterine cancer is found early, treatment is most effective. The most common sign of uterine cancer is bleeding that is not normal for you because of when it happens or how heavy it is. This could mean bleeding, even a little bit, after you have gone through menopause; periods that are longer than seven days; bleeding between periods; or any other bleeding that is longer or heavier than is normal for you.
Other symptoms, such as pain or pressure in your pelvis, also may occur if you have uterine cancer. If you have any of these symptoms, talk to your doctor, nurse, or other health care professional right away. They may be caused by something other than cancer, but the only way to know is to see your health care professional.
Cancer incidence trends among adults in the New York State (NYS) and associations with common population-level exposures.
An artificial intelligence tool correctly answered 83 percent of common genetic counseling questions, including those about genetic testing and genetic syndromes, a new study found.
The University of Miami today announced a transformational $50 million gift from Kenneth C. Griffin, Founder and Chief Executive Officer of Citadel and Founder of Griffin Catalyst, to Sylvester Comprehensive Cancer Center, part of the University of Miami Health System and the Miller School of Medicine.
A new research paper was published in Oncotarget's Volume 15 on February 22, 2024, entitled, "Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health."
In April, a dozen years after a federal agency classified formaldehyde a human carcinogen, the Food and Drug Administration is tentatively scheduled to unveil a proposal to consider banning the chemical in hair-straightening products.
Cleveland Clinic researchers have successfully developed a therapeutic peptide that blocks aggressive cancer cells from multiplying rapidly.
The numbers are stark and deeply troubling. Endometrial cancer -; which develops in the lining of the uterus (womb) and is sometimes called uterine cancer -; is on the rise in the U.S. In 1987, there were 35,000 cases annually.
This study identifies links between exposure to chemicals like PFAS, parabens, and phenols and increased cancer risk, particularly among women and across racial groups. The findings spotlight the role of environmental toxins in hormone-related cancers, suggesting new avenues for cancer prevention and mitigation strategies.
An international clinical trial exploring a new way to treat rare and aggressive gynaecological cancers has launched in Melbourne.
Today, the American Association for Cancer Research (AACR) released the 13th edition of its annual Cancer Progress Report, which chronicles how basic, translational, and clinical cancer research and cancer-related population sciences-;primarily supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI)-;remain vitally important to improving health and saving lives.
The National Comprehensive Cancer Network today announced the publication of NCCN Guidelines for Patients®: Hodgkin Lymphoma in Children.
In new findings from researchers at the American Cancer Society (ACS), non-Hispanic Black individuals diagnosed with a second primary cancer (SPC) experienced 21% higher cancer-related death rates and 41% higher cardiovascular-related death rates compared with their non-Hispanic White counterparts.
U.S. News & World Report ranks UCSF Health adult care among nation's top 10 hospitals in 7 specialties, Best in the West for neurology/neurosurgery and rheumatology.
Deanna Denham Hughes was stunned when she was diagnosed with ovarian cancer last year. She was only 32. She had no family history of cancer, and tests found no genetic link. Hughes wondered why she, an otherwise healthy Black mother of two, would develop a malignancy known as a "silent killer."
Compared with white women, Black women have elevated risks of being diagnosed with advanced uterine cancer—also known as endometrial cancer—and of developing aggressive tumors.
Women who used combined contraceptive pills were at greater risk of developing depression than women who did not, according to a new study from Uppsala University. Contraceptive pills increased women's risk by 73 per cent during the first two years of use.
Hispanic and non-Hispanic Black female survivors of breast cancer experience higher death rates after being diagnosed with a second primary cancer than members of other ethnic and racial groups, according to recent research from investigators at the Johns Hopkins Kimmel Cancer Center.
A new research perspective was published in Oncotarget's Volume 14 on May 4, 2023, entitled, "Using cancer proteomics data to identify gene candidates for therapeutic targeting."
A new research paper was published in Oncotarget's Volume 14 on May 4, 2023, entitled, "Human LY6 gene family: potential tumor-associated antigens and biomarkers of prognosis in uterine corpus endometrial carcinoma."
In a study published in the March 27, 2023, online edition of the New England Journal of Medicine, researchers at the University of California San Diego School of Medicine and Moores Cancer Center at UC San Diego Health found the combination of immunotherapy (pembrolizumab) and chemotherapy in patients with advanced or recurrent/advanced endometrial cancer resulted in a significant reduction in disease growth when compared with chemotherapy alone.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.